Neurodegenerative diseases represent promising targets for gene therapy approaches provided effective transfer vectors. In the present study, we evaluated the effectiveness of LacZ-expressing lentiviral vectors with two different internal promoters, the mouse phosphoglycerate kinase 1 (PGK) and cytomegalovirus (CMV), to infect striatal cells. The intrastriatal injection of lenti-␤-Gal vectors lead to 207, 400 ؎ 11,500 and 303,100 ؎ 4,300 infected cells in adult rats, respectively. Importantly, the ␤-galactosidase activity was higher in striatal extracts from PGK-LacZ-injected animals as compared to CMV-LacZ animals. The efficacy of the system was further examined with a potential therapeutic gene for the treatment of Huntington's disease, the human ciliary neurotrophic factor (CNTF). PGKLacZ-or PGK-CNTF-expressing viruses were stereotaxically injected into the striatum of rats, 3 weeks later the animals were unilaterally lesioned with 180 nmol of quinolinic acid (QA). Control animals displayed 148 ؎ 43 apomorphine-induced rotations ipsilateral to the lesion 5 days postlesion as compared to 26 ؎ 22 turns/45 min in the CNTF-treated group. The extent of the striatal damage was significantly diminished in the CNTF-treated rats as indicated by the 52 ؎ 9.7% decrease of the lesion volume and the sparing of DARPP-32, ChAT and NADPH-d neuronal populations. These results further establish that lentiviruses may represent an efficient gene delivery system for the screening of therapeutic molecules in Huntington's disease.
INTRODUCTION
Huntington's disease (HD) is an autosomal dominant inherited disorder involving the selective neuronal loss of striatal GABAergic output neurons and astrogliosis (Vonsattel and DiFiglia, 1998) . The disease is characterized by motor and cognitive disturbances as well as psychiatric manifestations which usually appear in adult life and progress over one to two decades. Huntingtin, the gene causing Huntington's disease has been cloned in 1993 and the mutation identified as an unstable (CAG)n repeat in the 5Ј coding region of the protein (The Huntington's disease collaborative research group, 1993). Despite these important progresses, opening the possibility to generate genetic models of the disease (Mangiarini et al., 1996; Reddy et al., 1998; Hodgson et al., 1999; Schilling et al., 1999; Yamamoto et al., 2000) , the mechanisms accounting for the selective striatal degeneration are still largely unknown and there is currently no treatment available.
Several lines of evidence suggest that energetic defects and oxidative damage leading to secondary excitotoxicity and cell death may be implicated in HD process (Beal, 1992; Gu et al., 1996) . Consistent with this hypothesis, the intrastriatal injection of the tryp-
